ICER finds first wave of new sickle cell drugs improves outcomes, but not cost-effective

A draft cost-effectiveness report from the Institute for Clinical and Economic Review found that the three marketed sickle cell drugs would have to take steep price cuts to hit the $150,000 per quality-adjusted life year threshold.

The group analyzed Adakveo crizanlizumab-tmca from Novartis AG (NYSE:NVS; SIX:NOVN), Oxbryta voxelotor from Global Blood Therapeutics Inc. (NASDAQ:GBT) and Endari L-glutamine from Emmaus Life Sciences Inc. (OTCQB:EMMA). Based on the list prices, Adakveo would require a 86% discount while Oxbryta would need a 96% discount and Endari a cut of 90% to meet the $150,000 threshold. ...